Differential white matter connectivity in early mild cognitive impairment according to CSF biomarkers

Jae-Sung Lim1, Young Ho Park2, Jae-Won Jang2

  • 1Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Republic of Korea; Department of Neurology, Seoul National University College of Medicine, Seoul, Republic of Korea.

Plos One
|March 12, 2014
PubMed

Insights

Certain early amnestic mild cognitive impairment (EMCI) patients show distinct white matter changes. Differences in cerebrospinal fluid (CSF) tau/amyloid ratios reveal varying connectivity, predicting dementia conversion.

Area of Science:

  • Neuroscience
  • Biomarkers
  • Neuroimaging

Background:

  • Mild cognitive impairment (MCI) is a heterogeneous condition.
  • A subset of MCI patients progress to dementia.
  • Cerebrospinal fluid (CSF) biomarkers can predict MCI conversion to dementia.

Purpose of the Study:

  • To investigate white matter connectivity differences in early amnestic MCI (EMCI) subgroups.
  • To analyze these differences based on CSF phosphorylated tau181p/amyloid beta1-42 ratios.
  • To understand the relationship between CSF biomarkers and white matter integrity in EMCI.

Main Methods:

  • Utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
  • Included 16 high-ratio EMCI, 25 low-ratio EMCI, and 20 normal control participants.
  • Analyzed diffusion tensor imaging (DTI) data and CSF profiles.

Main Results:

  • The low-ratio EMCI group exhibited increased radial diffusivity in the corpus callosum and longitudinal fasciculi compared to the high-ratio group.
  • The low-ratio EMCI group showed significantly increased mean, axial, and radial diffusivity in widespread white matter regions versus normal controls.
  • The high-ratio EMCI group did not differ from normal controls in white matter diffusivity.

Conclusions:

  • Significant white matter connectivity differences exist between EMCI subgroups.
  • These differences correlate with CSF phosphorylated tau181p/amyloid beta1-42 ratios.
  • CSF biomarker ratios may differentiate EMCI progression pathways.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35